The 22q11.2 deletion syndrome: a gene dosage perspective.

Antonio Baldini

Research output: Contribution to journalArticlepeer-review


The 22q11.2 deletion/DiGeorge syndrome is a relatively common "genomic" disorder that results from heterozygous deletion of a 3-Mbp segment of chromosome 22. Of the more than 30 genes deleted in this syndrome, TBX1 is the only one that has been found to be mutated in some patients with a phenotype that is very similar to that of patients with the full deletion, suggesting that TBX1 haploinsufficiency is a major contributor to the syndrome's phenotype. Multi- and single-gene mouse models have provided a considerable amount of information about the consequences of decreased and increased dosage of the genomic region (and in particular of the Tbx1 gene) on mouse embryonic development. Modified alleles of Tbx1, as well as conditional ablation strategies have been utilized to map in vivo the tissues and developmental stages most sensitive to gene dosage. These experiments have revealed substantially different sensitivity to gene dosage in different tissues and at different times, underlying the importance of the developmental context within which gene dosage reduction occurs.

Original languageEnglish
Pages (from-to)1881-1887
Number of pages7
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)
  • Medicine(all)


Dive into the research topics of 'The 22q11.2 deletion syndrome: a gene dosage perspective.'. Together they form a unique fingerprint.

Cite this